Skip to content
10-K

Annual Report

ACCENTIA BIOPHARMACEUTICALS INC

0001193125-11-345824

← back to feed
Filed
Dec 19, 2011 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2011 · Dec 15, 2011 75.24M sh
Capex FY 2011 · Sep 30, 2010 $72.13K
Operating Cash Flow FY 2011 · Sep 30, 2010 −$420.23K
Stockholders Equity FY 2011 · Sep 30, 2010 −$122.17M
Current Liabilities FY 2011 · Sep 30, 2010 $6.69M
Total Liabilities FY 2011 · Sep 30, 2010 $150.26M
Current Assets FY 2011 · Sep 30, 2010 $2.67M
Total Assets FY 2011 · Sep 30, 2010 $5.01M
Sga Expense FY 2011 · Sep 30, 2010 $4.22M
Rd Expense FY 2011 · Sep 30, 2010 $1.3M
Operating Income FY 2011 · Sep 30, 2010 −$3.6M
Gross Profit FY 2011 · Sep 30, 2010 $2.45M
Cost Of Revenue FY 2011 · Sep 30, 2010 $2.9M
Revenue FY 2011 · Sep 30, 2010 $5.36M
Cash And Equivalents FY 2011 · Sep 30, 2009 $325.35K